Accounts Payable and Related Party (Details Narrative) - USD ($) |
1 Months Ended | 3 Months Ended | ||
|---|---|---|---|---|
Mar. 31, 2025 |
Mar. 31, 2025 |
Mar. 31, 2024 |
Feb. 26, 2025 |
|
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Exercise price | $ 2.8375 | |||
| Cytovance Biologics Inc [Member] | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Issuance of pre-funded warrants | 326,251 | 326,251 | ||
| Exercise price | $ 0.0001 | $ 0.0001 | ||
| Payments in pre-funded warrants, at fair value | $ 847,000 | |||
| Legal Services Firm [Member] | ||||
| Defined Benefit Plan Disclosure [Line Items] | ||||
| Prior year unpaid fees | $ 1,000,000 | |||
| X | ||||||||||
- Definition Repayments of prefunded warrants at fair value. No definition available.
|
| X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of warrants or rights outstanding. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of cash outflow for fees classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|